Abstract
Recent studies indicate that antidepressant drugs with potent serotonin reuptake inhibiting properties are effective in reducing the symptoms of premenstrual syndrome (PMS). In order to elucidate whether all antidepressant drugs are equally effective in the treatment of PMS or whether potent serotonin reuptake inhibition is a prerequisite for reducing premenstrual complaints, women suffering from severe PMS were treated daily for three menstrual cycles with a selective serotonin reuptake inhibitor, paroxetine (n = 22), or with a selective noradrenaline reuptake inhibitor, maprotiline (n = 21); in addition, a placebo group was included (n = 22). Six symptoms (irritability, depressed mood, tension/anxiety, increased appetite/craving for carbohydrates, bloating, and breast tenderness) were rated by the participants daily throughout the study. With respect to all outcome measurements, the symptom reduction obtained with paroxetine was significantly superior to that obtained with placebo; with respect to irritability, increased appetite/carbohydrate craving, bloating, and breast tenderness, as well as global self-rating, paroxetine was significantly superior also to maprotiline. The clear-cut superiority of paroxetine over maprotiline indicates that not all antidepressant drugs are equally effective in the treatment of PMS; rather, like panic disorder and obsessive compulsive disorder, but in contrast to depression, PMS apparently responds better to serotonin reuptake inhibitors than to antidepressants with a noradrenergic profile.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eriksson, E., Hedberg, M., Andersch, B. et al. The Serotonin Reuptake Inhibitor Paroxetin Is Superior to the Noradrenaline Reuptake Inhibitor Maprotiline in the Treatment of Premenstrual Syndrome. Neuropsychopharmacol 12, 167–176 (1995). https://doi.org/10.1016/0893-133X(94)00076-C
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/0893-133X(94)00076-C
Keywords
This article is cited by
-
Use of hormonal contraceptives and antidepressants and risks of suicidal behavior and accidents among women with premenstrual disorders: a nationwide cohort study
BMC Medicine (2022)
-
Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention
CNS Drugs (2021)
-
Premenstrual syndrome: a single-blind study of treatment with buspirone versus fluoxetine
Archives of Gynecology and Obstetrics (2013)
-
ISPMD consensus on the management of premenstrual disorders
Archives of Women's Mental Health (2013)
-
The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study
Advances in Therapy (2008)